Forest Laboratories (NYSE:FRX) reported third quarter earnings before the bell Tuesday, posting an EPS of $1.04, beatinganalyst estimates of $1.01 per share. Revenues for the...
Forest Laboratories, Inc. (NYSE:FRX) announced today it has reached an agreement with Morgan Stanley (NYSE:MS) to repurchase $500 million of its common shares under an...
Forest Laboratories (NYSE:FRX) announced Monday that it will pay Jannsen Pharmaceutica $357 million in cash for payments attached to Bystolic, a high blood pressure drug....
Forest Laboratories (NYSE:FRX) announced that it has entered into an agreement with Morgan Stanley (NYSE:MS) to repurchase an additional $350 million of its common shares...
Forest Laboratories (NYSE:FRX)reported Q2 EPS of $0.91, missing consensus estimates of $0.99 per share. Revenues for the quarter rose 7.4% year-over-year to $1.17 billion, ahead...
Forest Labs (NYSE:FRX)reported Q2 EPS of $0.95, ex-items, topping consensus estimates of $0.86. Revenues in the quarter rose to $1.07 billion, vs. consensus estimates of...
Lupin has settled its litigation with Hatch Waxman regarding Memantine tablets. This could mean a potential upside of more than $200 million dollars for the...
Forest Laboratories (NYSE:FRX)reported Q4 EPS of $1.12, ahead of consensus estimates of $1.07 per share. Revenues for the quarter rose 9.7% year-over-year to $1.09 billion,...
April 26, 2011--Craig R Smith on Your World with Neil Cavuto (Guest Host: Stuart Varney) discussing the Obama Administration's attempt to oust the CEO of...
